Navigation Links
deCODE genetics Announces Webcast of Conference Call to Discuss Third Quarter 2008 Financial Results
Date:10/28/2008

REYKJAVIK, Iceland, October 28 /PRNewswire-FirstCall/ -- deCODE genetics, Inc. (Nasdaq:DCGN) today announced that it will report its third quarter 2008 financial results in a press release to be issued on Thursday, November 6, after the close of the market in New York. The company will host a live webcast of its conference call to discuss these results and recent operating highlights on Friday, November 7, at 8am EST/1pm GMT.

The webcast can be accessed through the Investors page of deCODE's website, http://www.decode.com, or through http://www.earnings.com. Please log in to the webcast 15 minutes prior to the scheduled start of the call. The call will be archived for at least a week on each site. For those unable to listen to the webcast because of company firewall or other issues, a digitized audio replay will also be available by telephone from approximately 11:30am ET on Friday, November 7 and for one week thereafter. The dial-in replay numbers are: 1-(800)-475-6701 in the U.S., and +1-320-365-3844 for those calling from outside the U.S. The access code is 967723.

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results, and the timing of events, to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to our ability to obtain financing and to form collaborative relationships, the effect of a potential delisting of our common stock from The Nasdaq Global Market, uncertainty regarding potential future deterioration in the market for auction rate securities which could negatively affect our cash position and result in additional permanent impairment charges, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10-K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. deCODE undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.

Contacts:

deCODE genetics,

Gisli Arnason,

+354-570-1825,

gisli.arnason@decode.is .


'/>"/>
SOURCE deCODE genetics Inc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. deCODE Discovery Sheds Light on Risk of the Most Common Form of Skin Cancer
2. deCODE Receives Nasdaq Deficiency Notice Relating to Market Value
3. Researchers decode viral process that prepares cells for HIV infection
4. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Healthcare Conference 2008
5. deCODE genetics Announces Second Quarter 2008 Financial Results
6. deCODE genetics Announces Webcast of Conference Call to Discuss Second Quarter 2008 Financial Results
7. deCODE genetics to Webcast Presentations at Annual R&D Event
8. deCODE genetics to Webcast Presentation at Piper Jaffray Europe Conference
9. deCODE genetics Announces First Quarter 2008 Financial Results
10. deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor-Positive Breast Cancer
11. deCODE Lauds Federal Legislation to Ban Discrimination on the Basis of Genetic Information
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... 2017  Ascendis Pharma A/S (Nasdaq: ASND), a ... to address significant unmet medical needs in rare ... year ended December 31, 2016. ... as we broadened our pipeline and pursued our ... company with an initial focus on endocrinology," said ...
(Date:3/22/2017)... 22, 2017 The global chronic ... research report by Transparency Market Research (TMR). The top ... and AbbVie Inc., accounted for a share of only ... in this market are focusing aggressively on mergers, acquisitions, ... is likely to lead to market consolidation in the ...
(Date:3/22/2017)... ... March 21, 2017 , ... Premier executive recruitment firm, ... Science Search Firm by Hunt Scanlon Media. , Hunt Scanlon Media is ... most widely referenced global news source in the human capital sector. , “It is ...
(Date:3/22/2017)... , ... March 21, 2017 , ... The Conference Forum ... (CMO Summit) to be held on May 10-11, 2017, at the Colonnade Hotel in ... specifically for Chief Medical Officer peer-to-peer learning, benchmarking and support. , “The Chief Medical ...
Breaking Biology Technology:
(Date:3/2/2017)... Summary This report provides all the ... interests and activities since 2010. ... Read the full report: http://www.reportlinker.com/p03605615-summary/view-report.html ... report provides an in-depth insight into the partnering activity of ... On demand company reports are prepared upon purchase to ensure ...
(Date:3/2/2017)... Australia , March 2, 2017 Australian ... Ltd (ASX: CYP), has signed an agreement with ... from the Monash Biomedicine Discovery Institute and Department of ... to conduct a further preclinical study to support the ... treatment of asthma.  Asthma is a ...
(Date:2/28/2017)... -- News solutions for biometrics, bag drop and New ... At ... 16 March, Materna will present its complete end-to-end passenger journey, ... a real benefit for passengers. To accelerate the whole passenger ... point solutions to take passengers through the complete integrated process ...
Breaking Biology News(10 mins):